Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Core Insights - Phio Pharmaceuticals announced positive results from its Phase 1b clinical trial of PH-762, showing a complete pathologic response (100% tumor clearance) in 2 out of 3 patients with cutaneous squamous cell carcinoma (cSCC) in the third dose cohort [1][2][3] - The trial aims to evaluate the safety and tolerability of PH-762 as a neoadjuvant treatment for various stages of cSCC, melanoma, and Merkel cell carcinoma [2][7] - The ongoing trial has treated a total of 10 patients, with 4 achieving complete pathologic response and others showing varying degrees of tumor clearance [3][4] Company Overview - Phio Pharmaceuticals is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® gene silencing technology [1][6] - The lead clinical program, PH-762, targets the PD-1 gene to enhance immune response against cancer cells [6] - The company plans to present trial results at the Society for Investigative Dermatology Annual Meeting on May 10, 2025 [6] Clinical Trial Details - The trial has not reported any dose-limiting toxicities or significant adverse effects, indicating a favorable safety profile for PH-762 [4][5] - The fourth cohort of the trial is currently enrolling patients, with expectations to complete enrollment by the third quarter of 2025 [4] - The positive pathologic responses observed in the trial support the potential of PH-762 as a non-surgical treatment option for skin cancers [2][5]